Statin Therapy for Primary and Secondary Prevention in Older Adults.

In a post-hoc analysis of participants 65 years or older there was no benefit of pravastatin in reducing CV events, while in those 75 years of age or older there was a nonsignificant trend toward increased all-cause mortality [ 7 ].

also in 5,406 other papers

In patients aged 75 years or older the risk of a major vascular event was reduced by 8% which did not reach statistical significance (95% CI, 0.73–1.16).

also in 111,027 other papers